Kyverna Therapeutics (KYTX) Accumulated Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 1.14% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (up 1.14% YoY), and the FY2025 full-year result was $10.0 million, up 104.59% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.1 million, down from $10.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.0 million in Q4 2025 and bottomed at $1.4 million in Q1 2024.
• The 4-year median for Accumulated Expenses is $3.8 million (2024), against an average of $4.4 million.
• The widest annual swing landed in 2025, when Accumulated Expenses surged 125.9%; it then gained 1.14% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $2.8 million in 2023, then surged by 73.65% to $4.9 million in 2024, then jumped by 104.59% to $10.0 million in 2025, then slumped by 68.83% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $10.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.

Peer Comparison